Research programme: ubiquitin ligase inhibitors - Proteologics

Drug Profile

Research programme: ubiquitin ligase inhibitors - Proteologics

Alternative Names: Midline-1 inhibitor - Proteologics; PRT14-2; PRT3; PRT42; PRT44; TRIM 18 inhibitor - Proteologics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Proteologics
  • Developer GlaxoSmithKline; Proteologics; University of Newcastle, Australia
  • Class Small molecules
  • Mechanism of Action HIV replication inhibitors; Ubiquitin-protein ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Asthma; Cancer
  • Discontinued HIV infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Asthma in Australia
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Asthma in Israel
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top